Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial.
The aim of this study was to assess the glucose-lowering and lipid-modifying effects, and safety profile of lobeglitazone, a novel peroxisome proliferator-activated receptor- γ agonist, compared to placebo as a monotherapy in patients with type 2 diabetes.In this 24-week, multicenter, randomized, do...
Main Authors: | Sin Gon Kim, Doo Man Kim, Jeong-Taek Woo, Hak Chul Jang, Choon Hee Chung, Kyung Soo Ko, Jeong Hyun Park, Yong Soo Park, Sang Jin Kim, Dong Seop Choi |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3988010?pdf=render |
Similar Items
-
Effects of Lobeglitazone, a Novel Thiazolidinedione, on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus over 52 Weeks
by: Soo Lim, et al.
Published: (2017-10-01) -
Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
by: Jaehyun Bae, et al.
Published: (2021-05-01) -
Treatment with Lobeglitazone Attenuates Hepatic Steatosis in Diet-Induced Obese Mice
by: Sorim Choung, et al.
Published: (2018-01-01) -
Effects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice
by: Kyoung Min Kim, et al.
Published: (2017-09-01) -
Lobeglitazone Attenuates Airway Inflammation and Mucus Hypersecretion in a Murine Model of Ovalbumin-Induced Asthma
by: Na-Rae Shin, et al.
Published: (2018-08-01)